Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National Center for Research Resources (NCRR) Scripps Clinic |
---|---|
Information provided by: | Office of Rare Diseases (ORD) |
ClinicalTrials.gov Identifier: | NCT00004762 |
OBJECTIVES:
I. Evaluate the effects of cladribine (2-chlorodeoxyadenosine; 2-CdA) on biochemical, radiologic, and histologic parameters in patients with early stage primary sclerosing cholangitis.
Condition | Intervention | Phase |
---|---|---|
Cholangitis, Sclerosing |
Drug: cladribine |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Stage I-III primary sclerosing cholangitis
Radiologically and pathologically documented
No concomitant liver disease, e.g.:
--Prior/Concurrent Therapy--
No concurrent immunosuppressives
--Patient Characteristics--
Hematopoietic:
Other:
Endoscopic retrograde cholangiopancreatography within 36 months prior to registration
Liver biopsy within 12 months prior to registration
Study ID Numbers: | 199/11707, SCRF-94304 |
Study First Received: | February 24, 2000 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00004762 |
Health Authority: | United States: Federal Government |
gastrointestinal disorders primary sclerosing cholangitis rare disease |
Cladribine Primary sclerosing cholangitis Cholangitis Digestive System Diseases Cholangitis, Sclerosing |
Bile Duct Diseases Gastrointestinal Diseases Biliary Tract Diseases Rare Diseases 2-chloro-3'-deoxyadenosine |
Immunologic Factors Antineoplastic Agents Therapeutic Uses |
Physiological Effects of Drugs Immunosuppressive Agents Pharmacologic Actions |